Skip to main content

Johnson & Johnson expects no new Covid vaccine revenue, after shots drive earnings beat

J&J's unpopular Covid vaccine appeared to bear its last fruit during the first quarter, contributing $747 million in sales.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.